AU2001249672A1 - Method for using 2- or 3-aryl substituted imidazo(1,2-a) pyridines as h3 antagonists - Google Patents

Method for using 2- or 3-aryl substituted imidazo(1,2-a) pyridines as h3 antagonists

Info

Publication number
AU2001249672A1
AU2001249672A1 AU2001249672A AU4967201A AU2001249672A1 AU 2001249672 A1 AU2001249672 A1 AU 2001249672A1 AU 2001249672 A AU2001249672 A AU 2001249672A AU 4967201 A AU4967201 A AU 4967201A AU 2001249672 A1 AU2001249672 A1 AU 2001249672A1
Authority
AU
Australia
Prior art keywords
pyridines
antagonists
aryl substituted
substituted imidazo
imidazo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001249672A
Inventor
J. Guy Breitenbucher
Nicholas I Carruthers
Xiaobing Li
Timothy W Lovenberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceuticals Inc
Original Assignee
Ortho McNeil Pharmaceutical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho McNeil Pharmaceutical Inc filed Critical Ortho McNeil Pharmaceutical Inc
Publication of AU2001249672A1 publication Critical patent/AU2001249672A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
AU2001249672A 2000-03-31 2001-03-29 Method for using 2- or 3-aryl substituted imidazo(1,2-a) pyridines as h3 antagonists Abandoned AU2001249672A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US19407100P 2000-03-31 2000-03-31
US60194071 2000-03-31
US27229001P 2001-02-28 2001-02-28
US60272290 2001-02-28
PCT/US2001/010319 WO2001074813A2 (en) 2000-03-31 2001-03-29 METHOD FOR USING 2- OR 3-ARYL SUBSTITUTED IMIDAZO[1,2-a] PYRIDINES AS H3 ANTAGONISTS

Publications (1)

Publication Number Publication Date
AU2001249672A1 true AU2001249672A1 (en) 2001-10-15

Family

ID=26889669

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001249672A Abandoned AU2001249672A1 (en) 2000-03-31 2001-03-29 Method for using 2- or 3-aryl substituted imidazo(1,2-a) pyridines as h3 antagonists

Country Status (3)

Country Link
US (1) US6489337B1 (en)
AU (1) AU2001249672A1 (en)
WO (1) WO2001074813A2 (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7208497B2 (en) 2001-07-02 2007-04-24 Novo Nordisk A/S Substituted piperazines and diazepanes
EP1430027B1 (en) 2001-09-14 2010-09-01 High Point Pharmaceuticals, LLC Novel aminoazetidine, -pyrrolidine and -piperidine derivatives
US6673829B2 (en) 2001-09-14 2004-01-06 Novo Nordisk A/S Aminoazetidine,-pyrrolidine and -piperidine derivatives
DE10247271A1 (en) * 2002-10-10 2004-08-26 Grünenthal GmbH Use of new and known 7-(methyl or trifluoromethyl)-imidazo-(1,2-a)-pyridines as nitrogen monoxide synthase inhibitors useful e.g. for treating migraine, neurodegenerative diseases, inflammatory pain, diabetes or cancer
WO2004087938A1 (en) * 2003-03-31 2004-10-14 Meiji Seika Kaisha, Ltd. Novel physiologically active substances pf1270a, b and c
US8501739B2 (en) 2005-07-04 2013-08-06 High Point Pharmaceuticals, Llc Medicaments
AU2006326135A1 (en) * 2005-12-15 2007-06-21 F. Hoffmann-La Roche Ag Pyrrolo[2,3-c]pyridine derivatives
EP2019103B1 (en) * 2006-05-19 2011-11-30 Nihon Medi-Physics Co., Ltd. Compound having affinity for amyloid
JP5694661B2 (en) 2006-05-29 2015-04-01 ハイ ポイント ファーマシューティカルズ，リミティド ライアビリティ カンパニー 3- (1,3-Benzodioxol-5-yl) -6- (4-cyclopropylpiperazin-1-yl) -pyridazine, its salt, its solvate, and its use as a histamine H3 receptor antagonist Law
TW200811175A (en) * 2006-06-21 2008-03-01 Nihon Mediphysics Co Ltd Novel compound with affinity with amyloid
EP2042501B1 (en) * 2006-06-21 2017-04-12 Nihon Medi-Physics Co., Ltd. Compound having affinity for amyloid
FR2903107B1 (en) 2006-07-03 2008-08-22 Sanofi Aventis Sa IMIDAZOPYRIDINE-2-CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE
FR2903105A1 (en) * 2006-07-03 2008-01-04 Sanofi Aventis Sa 2-BENZOYL-IMIDAZOPYRIDINE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE
FR2906250B1 (en) * 2006-09-22 2008-10-31 Sanofi Aventis Sa DERIVATIVES OF 2-ARYL-6PHENYL-IMIDAZO (1,2-A) PYRIDINES, THEIR PREPARATION AND THEIR THERAPEUTIC USE
US8207189B2 (en) 2006-11-30 2012-06-26 Nihon Medi-Physics Co., Ltd. Compound having affinity for amyloid
TWI406674B (en) 2007-02-13 2013-09-01 Nihon Mediphysics Co Ltd Method for manufacturing diagnostic radiographic diagnostic agents
EP2014656A3 (en) 2007-06-11 2011-08-24 High Point Pharmaceuticals, LLC New heteocyclic h3 antagonists
AU2008314870A1 (en) * 2007-10-24 2009-04-30 Nihon Medi-Physics Co., Ltd. Novel compound having affinity for amyloid
TW200918101A (en) 2007-10-26 2009-05-01 Nihon Mediphysics Co Ltd Novel compound having affinity for amyloid
WO2009057576A1 (en) * 2007-10-30 2009-05-07 Nihon Medi-Physics Co., Ltd. Use of novel compound having affinity for amyloid, and process for production of the same
KR20100101577A (en) * 2007-10-30 2010-09-17 니혼 메디피직스 가부시키가이샤 Utilization of novel compounds with amyloid affinity and method of producing the same
WO2013151982A1 (en) 2012-04-03 2013-10-10 Arena Pharmaceuticals, Inc. Methods and compounds useful in treating pruritus, and methods for identifying such compounds
CN114874084B (en) * 2022-01-28 2023-12-19 浙江普洛家园药业有限公司 Preparation method of bupropion hydrochloride impurity F

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5910675B2 (en) * 1976-03-22 1984-03-10 ウェルファイド株式会社 Aralkylamine derivatives
US5182291A (en) 1986-02-14 1993-01-26 Sanofi Pyrozala-pyridyl aminoabkoxyphenol compounds
US4833149A (en) * 1986-09-22 1989-05-23 Ortho Pharmaceutical Corporation 2- or 3-aryl substituted imidazo[1,2-a]pyridines
US4727145A (en) 1986-09-22 1988-02-23 Ortho Pharmaceutical Corporation 2- Or 3- aryl substituted imidazo [1,2-a]pyridines
EP0289371B1 (en) * 1987-03-27 1991-09-25 Synthelabo Imidazopyridine derivatives, their preparation and therapeutical use
US4880824A (en) 1987-09-21 1989-11-14 Ortho Pharmaceutical Corporation Phenyl and benzoyl substituted imidazo-fused heterocyclic calcium channel blockers
EP0978512A1 (en) 1998-07-29 2000-02-09 Societe Civile Bioprojet Non-imidazole aryloxy (or arylthio) alkylamines as histamine H3-receptor antagonists and their therapeutic applications
DE60128211T2 (en) * 2000-03-31 2008-01-10 Ortho-Mcneil Pharmaceutical, Inc. PHENYL-SUBSTITUTED IMIDAZOPYRIDINE

Also Published As

Publication number Publication date
WO2001074813A2 (en) 2001-10-11
US6489337B1 (en) 2002-12-03
WO2001074813A3 (en) 2002-03-21

Similar Documents

Publication Publication Date Title
AU2001249672A1 (en) Method for using 2- or 3-aryl substituted imidazo(1,2-a) pyridines as h3 antagonists
AU2002222293A1 (en) Pyrazolo(3,4-c)pyridines as gsk-3 inhibitors
ZA200306341B (en) Imidazo (1,2-a)-pyridine derivatives as mGluR5 antagonists.
ZA200605901B (en) Pyrazolo [3,4-B] pyridine compounds, and their use as phosphodiesterase inhibitors
AU2001259707A1 (en) 6,5-fused bicyclic heterocycles
EE200200192A (en) 5- (2-Substituted-5-heterocyclylsulfonylpyrid-3-yl) dihydropyrazolo [4,3-d] pyrimidin-7-ones as phosphodiesterase inhibitors
AU2003233519A1 (en) Process for imidazo(4,5-c)pyridin-4-amines
AU2004209447A8 (en) Pyrazolo`1,5-a!`1,3,5!triazine derivatives as cannabinoid receptor ligands
IL170680A0 (en) 8 - SUBSTITUTED - 6,7,8,9 -TETRAHYDROPYRIMIDO [1,2-a] PYRIMIDIN - 4 - ONE DERIVATIVES
WO2003051362A3 (en) Polymorphs of clopidogrel hydrogensulfate
AP2004002981A0 (en) Method for the preparation of hexahydro-furo [2,3-B]furan-3-o1.
ZA200507192B (en) Substituted 8-perfluoroalkyl-6,7,8,9-tetrahydropyrimido [1,2-A] pyrimidin-4-one derivatives
AU4203500A (en) Pyrazolopyrimidines as crf antagonists
WO2001074810A3 (en) Method for using 2-aryloxyalkylaminobenzoxazoles and 2-aryloxyalkylaminobenzothiazoles as h3 antagonists
AU2003220190A1 (en) Pyrazolo(1,5-a)pyridine derivatives as neurotransmitter modulators
IL163287A (en) HETEROARYL SUBSTITUTED 2 - PYRIDINYL AND 2 - PYRIMIDINYL - 6,7,8,9 - TETRAHYDROPYRIMIDO [1,2-a] PYRIMIDIN - 4 - ONE DERIVATIVES
PT1674456E (en) Use of 2-fluoro- 3-ketoesters for preparing 3-fluoro-6,7,8,9-tetrahydro-4-h-pyrimdo[1,2-a]pyrimidin-4-ones
AU2002221753A1 (en) Novel 7-azaindoles, use thereof as phosphodiesterase 4 inhibitors and method for producing the same
AU4331500A (en) Pyrazolotriazines as crf antagonists
MXPA03008965A (en) Use of substituted imidazo[1,2-a]-pyridine compounds as medicaments.
PL370565A1 (en) 5-methoxy-8-aryl-[1,2,4] triazolo [1,5-a] pyridine derivatives as adenosine receptor antagonists
AU2003230758A1 (en) 5h-benzo(4,5)cyclohepta(1,2-b)pyridine nmda/nr2b antagonists
ZA200205596B (en) Octahydro-2H-Pyrido[1,2-A]pyrazine compounds, a process for their preparation and pharmaceutical compositions containing them.
AU2673201A (en) Alpha-arylethylpiperazine derivatives as neurokinin antagonists
AU6831500A (en) 1h-pirido[3, 4-b]indol-1-one derivatives